Results 201 to 210 of about 26,436 (212)

Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies

Expert Review of Anticancer Therapy, 2022
Robert Motzer, Takuji Okusaka, Seiichi Hayato   +2 more
exaly  

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Lancet, The, 2018
Fabio Piscaglia, Joong-Won Park, Masatoshi Kudo   +2 more
exaly  

Genome-Scale CRISPR screen identifies LAPTM5 driving lenvatinib resistance in hepatocellular carcinoma

Autophagy, 2023
exaly  

Investigation on the binding behavior between BSA and lenvatinib with the help of various spectroscopic and in silico methods

Journal of Molecular Structure, 2020
Jie-Hua Shi, Bao-Li Wang, Song‐Bo Kou
exaly  

Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid

European Journal of Cancer, 2017
Naomi Kiyota, Makoto Tahara, Steven I. Sherman   +2 more
exaly  

Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer

Cancer Science, 2015
Naomi Kiyota, Makoto Tahara, Steven I. Sherman   +2 more
exaly  

Lenvatinib

Reactions Weekly, 2019
openaire   +2 more sources

Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer

European Journal of Cancer, 2019
Marcia S Brose, Makoto Tahara, Lori J Wirth   +2 more
exaly  

Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model

Cancer Science, 2018
Yasuhiro Funahashi, Yu Kato, Takayuki Kimura   +2 more
exaly  

Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer

British Journal of Clinical Pharmacology, 2016
Jaume Capdevila, Barbara Jarząb, Robert Shumaker   +2 more
exaly